uniQure applies for U.S. approval after FDA reverses stance
uniQure said it has applied for U.S. approval of its experimental Huntington’s disease gene therapy after the FDA reversed its earlier position; shares were up 5% in premarket trading.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.